Ypsomed

What Ypsomed does

Ypsomed is a Switzerland-headquartered, publicly-listed medical device company (SIX: YPSN) that develops and manufactures self-injection drug delivery systems—including pen injectors, two-step prefilled autoinjectors (YpsoMate in 1 mL, 2.25 mL and 5.5 mL variants), the YpsoLoop circular autoinjector, and the 10 mL YpsoDose patch/wearable injector—plus digital add-ons such as the FDA-cleared SmartPilot connectivity module. The company serves pharmaceutical and biotech customers exclusively on a B2B basis, with products integrated into GLP-1 obesity/diabetes, insulin, biologic and biosimilar therapies; named customers include Novo Nordisk, Sanofi (over 1 billion SoloSTAR pen components produced), Abbott, Dexcom, Insulet, BD, SCHOTT Pharma, Stevanato Group and CamDiab. Revenue is generated through hardware sales of injection devices, project/development fees (CHF 85.7 million from a record 44 new customer projects in FY2025/26), and a contract-manufacturing stream (e.g., SoloSTAR for Sanofi) that is being deliberately phased out and moved to the Others segment from FY2026/27 as Ypsomed completes its pivot to pure-play self-injection.

Following the July 2025 sale of mylife Diabetes Care AG to TecMed AG for up to CHF 420 million including earn-out, Ypsomed operates exclusively in injectable drug delivery, with FY2025/26 group revenue of CHF 731.0 million, Delivery Systems revenue of CHF 601.5 million (+20% YoY), Delivery Systems EBIT of CHF 195.5 million (32.5% margin), group EBIT of CHF 246.1 million, ROCE of 20% and net debt/EBITDA of 0.8x. Manufacturing is anchored in Burgdorf and Solothurn (Switzerland) and Schwerin (Germany), with a new Changzhou facility in China (up to 100 million units/year) and a CHF 200 million Holly Springs, North Carolina plant under development for US supply from end of 2027; medium-term targets are CHF 0.9–1.1 billion revenue and CHF 280–340 million EBIT (≥30% margin) by 2029/30, supported by a CHF 150 million completed share buyback and CHF 295.6 million FY2025/26 capex.

Name

Ypsomed

Legal name

Ypsomed AG

Website

https://ypsomed.com

Company type

Public

Founded year

1984

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Ypsomed is a Swiss-listed medical device company that designs and manufactures self-injection drug delivery systems—pen injectors, prefilled autoinjectors and wearable patch injectors—sold exclusively B2B to pharmaceutical and biotech companies for use with GLP-1, insulin and biologic therapies.

Ownership category

akta.pro rank

Product category

Self-injection drug delivery devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Auto-Injectors (Disposable & Reusable) (HLAHAIAB)

akta.pro secondary industries

Wearable Injectors & On-Body Delivery Systems (HLAHAIAE), Pen Injectors (Insulin/GLP-1/Other Pens) (HLAHAIAC), Drug Delivery Connectivity, Sensors & Digital Add-Ons (Smart Caps/Companion Apps) (HLAHAIAM), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

Keywords

• Self-injection devices
• Autoinjector platforms
• Pen injectors
• Drug delivery systems
• Wearable injectors

Headquarters

HQ city

Burgdorf

HQ country

Switzerland

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Delivery Systems Product Sales: Revenue from sale of pen injectors, autoinjectors, and wearable injectors to pharmaceutical and biotech customers. Growth driven by GLP-1 medications and biologics market expansion. FY2025/26 Delivery Systems revenue of CHF 601.5 million representing 20% year-on-year growth.
2. Project Business / Development Fees: Revenue from new customer project development and capacity reservation fees from pharmaceutical customers. Record 44 new customer projects secured in FY2025/26 with project business revenue of CHF 85.7 million.
3. Contract Manufacturing: Manufacturing services for pharmaceutical companies including production of pen components (e.g., SoloSTAR for Sanofi). Being phased out and reported in segment Others for FY2026/27.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels10 records

Core offering

Ypsomed designs, develops, and manufactures self-injection drug delivery systems — pen injectors, prefilled autoinjectors, and wearable patch injectors — together with digital connectivity add-ons, and sells them exclusively in large batches to pharmaceutical and biotechnology companies for use with their drug products. The company leverages a proprietary modular platform architecture to customize delivery devices rapidly and supports customers with regulatory, clinical trial, and manufacturing services across global facilities in Switzerland, Germany, China, and a forthcoming U.S. site.

Product overview

Ypsomed is the leading developer and manufacturer of self-injection systems for liquid medications, offering the most comprehensive and innovative platform portfolio for pens, autoinjectors, and on-body devices. The product portfolio includes pen injectors (YpsoPen, ServoPen, UnoPen, YpsoFlow, YpsoDot, FixPen, LyoTwist), autoinjectors (YpsoMate in 1 mL, 2.25 mL, and 5.5 mL variants, YpsoLoop), wearable injectors (YpsoDose), and digital health solutions (SmartPilot connectivity add-on, CliniPilot, therapy management, connected devices). The company also operates an Innovation Hub developing sustainable solutions including reusable mechanical autoinjectors and circularity initiatives. Ypsomed serves pharmaceutical and biotech companies with contract manufacturing and development services, including the Clear-to-Clinic program for clinical trials.

Differentiator

Problem solved

Functional benefit

Brands

• UnoPen: Prefilled variable dose pen injector for GLP-1 and peptide therapies
• ServoPen
• YpsoPen
• YpsoFlow
• FixPen
• LyoTwist
• VarioJect
• YpsoLoop
• YpsoMate
• YpsoMate 2.25/Pro
• YpsoMate 5.5
• SmartPilot
• CliniPilot
• YpsoDose
• YpsoDot
• Clear to Clinic
• Reusable Mechanical Autoinjector

Products and services

• YpsoPen Reusable pen injector for GLP-1, insulin and other peptide therapies, featuring variable dose functionality for pharmaceutical and biotech customers.
• ServoPen Reusable pen injector designed for GLP-1, insulin and other peptide therapies, supplied to pharmaceutical customers.
• UnoPen Prefilled variable dose pen injector for GLP-1 and peptide therapies, offering single-use convenience for pharmaceutical customers.
• YpsoFlow Prefilled, spring-powered pen injector designed for peptide therapies, launched as a new platform in 2025 for pharmaceutical and biotech customers.
• YpsoDot Next-generation pull-push pen injector launched in 2025 for pharmaceutical and biotech customers.
• FixPen Prefilled fixed-dose pen injector for peptide therapies, supplied to pharmaceutical customers.
• LyoTwist Reconstitution auto-injector for lyophilized drugs, enabling self-administration of drugs requiring reconstitution by patients.
• YpsoMate (1 mL) 1 mL two-step prefilled autoinjector for GLP-1 and other medications, featuring push-on-skin activation; widely used by pharmaceutical customers including Novo Nordisk (long-term supply contract).
• YpsoMate 2.25 / Pro 2.25 mL two-step prefilled autoinjector for biologics and other higher-volume medications, supplied to pharmaceutical customers.
• YpsoMate 5.5 5.5 mL large-volume prefilled autoinjector for biologics, designed for high-dose subcutaneous injections in oncology, autoimmune, rare diseases, and metabolic disorders.
• YpsoLoop First autoinjector platform designed for circularity, with 1 mL and 2 mL versions enabling automated disassembly and efficient recycling while offering prefilled two-step autoinjector convenience. Awarded the CPHI Innovation Award.
• VarioJect Versatile variable dose autoinjector for syringes and cartridges, supplied to pharmaceutical customers.
• YpsoDose 10 mL prefilled and pre-assembled patch injector for biologics, enabling subcutaneous delivery of larger volumes for pharmaceutical and biotech customers.
• SmartPilot for YpsoMate FDA-cleared digital connectivity add-on that transforms the YpsoMate autoinjector into a connected system that automatically captures and transmits injection data for therapy monitoring and adherence.
• Clear-to-Clinic Program enabling clinic-ready YpsoMate 1 mL and YpsoMate 2.25 mL autoinjectors in clinical trials to accelerate, simplify and de-risk pharmaceutical development programs.

Quantifiable outcome

• 33.6% growth in commercial autoinjector sales
• +4 more outcomes

Named customers6 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration8 records

Feature6 records

Partnerships

Nine partnerships are on record, tiered strategic and core.

• Stevanato GroupstrategicTechnology or Integration · 1 June 2026Collaboration on integration of EZ-fill prefilled syringes into YpsoMate platform and expanding capacity for high-viscosity formulations for large-volume biologic delivery.
• Digital Medicine Society (DiMe)strategicStrategic or Co-development Partner · 1 April 2026Founding partner in DiMe's Optimizing Direct-to-Patient (DTP) Strategies initiative to establish operational, regulatory, and evidence-based foundations for scaling direct-to-patient healthcare models responsibly.
• AbbottcoreTechnology or Integration · 1 November 2025Integration of Abbott's FreeStyle Libre CGM sensors with Ypsomed's mylife Loop automated insulin delivery system. FreeStyle Libre 2 and 3 integrated with Tandem's t:slim X2 pump and Ypsomed's mylife Loop for automated insulin dosing. Partnership with CamDiab also integrated in Germany.
• BD (Becton, Dickinson and Company)coreTechnology or Integration · 1 October 2024Partnership to develop large-volume glass syringes for high-dose biologics. BD's Neopak XtraFlow glass prefillable syringes integrated with Ypsomed's YpsoMate 5.5 autoinjector platform for high-viscosity biologic drug delivery. Expanded in 2026 with 5.5mL version development featuring shorter 8mm needle and thinner wall cannulas.
• Sidekick HealthstrategicTechnology or Integration · 1 January 2023Partnership combining Ypsomed's injection systems with Sidekick's digital health, behavioral economics and gamification expertise to offer motivating and personalized patient experience for chronic disease management.
• S3 Connected HealthstrategicTechnology or Integration · 1 January 2023Partnership to expand digital health offering for pharmaceutical companies to support patients with acute and chronic diseases through integrated device and digital health solutions.
• CamDiab LtdcoreTechnology or Integration · 1 January 2022Cooperation with CamDiab, developer of CamAPS FX algorithm, to launch automated insulin dosing system for mylife YpsoPump users. Self-learning adaptive algorithm running on smartphone for better glucose control. Solution available for Android and iOS.
• DexcomcoreTechnology or Integration · 1 January 2020Partnership to establish hybrid closed-loop system for diabetes therapy. Glucose data from Dexcom CGM sensors integrated directly into mylife app for automated insulin delivery.
• Insulet CorporationstrategicChannel Partner/ Reseller/ Distributor · 1 January 2010Exclusive distribution of OmniPod patch pump from Insulet in Europe, China and Australia. The mylife OmniPod is glued directly to the skin at injection site. Built customer base of 70,000 patients by 2018.

Scale indicators24 records

Recent moves11 records

Expansion highlights5 records

Direct peers

• BD (Becton, Dickinson and Company) – Pharmaceutical Systems: BD Pharmaceutical Systems is the global leader in prefillable syringe systems and is Ypsomed's direct development partner (Neopak XtraFlow 5.5mL for YpsoMate 5.5) and direct competitor in drug-delivery combination products serving pharma and biotech customers.
• West Pharmaceutical Services: West Pharmaceutical Services is a leading provider of drug containment and delivery components including elastomeric stoppers, seals, and self-injection device platforms (e.g., SmartDose, Confidose), directly competing with Ypsomed's autoinjector and wearable injector portfolio.
• SHL Medical: SHL Medical is one of Ypsomed's closest direct competitors in autoinjector and pen-injector platforms, supplying major pharma companies with devices like Molly, DAI, and reusable pen systems globally.
• Stevanato Group: Stevanato Group is an Italian drug containment and delivery player offering glass syringes (EZ-fill), vial, and device platforms; a recent Ypsomed collaboration expands EZ-fill integration with YpsoMate for high-viscosity biologics, positioning Stevanato as both partner and adjacent competitor.
• Gerresheimer: Gerresheimer is a top-tier global supplier of pharmaceutical glass and plastic primary packaging plus drug-delivery devices (incl. syringe systems and autoinjectors), competing with Ypsomed for prefilled syringe and combination-product business.
• SCHOTT Pharma: SCHOTT Pharma supplies pharmaceutical glass including syringQ BioPure prefillable syringes; the 5.5mL syringe integrated with YpsoMate 5.5 positions SCHOTT as a key component partner and competitor for prefilled syringe contents feeding Ypsomed-class devices.
• Owen Mumford: Owen Mumford is a UK-headquartered specialist in pen injectors and autoinjectors (e.g., Autoject, Uniject) for pharma and consumer self-care markets, competing with Ypsomed across both reusable and disposable self-injection platforms.

Emerging players

• Haselmeier: Haselmeier is a German specialist in subcutaneous injection devices including pen injectors and autoinjectors (e.g., Sub-Q, Berpu), competing in pharma drug-delivery with similar platform-customization model to Ypsomed.

Broad incumbents

• Aptar Pharma (Crystal Simple Dreams / Activ-Film): Aptar Pharma is the drug-delivery arm of AptarGroup offering elastomeric components, prefilled syringe components, and connected drug-delivery platforms (e.g., PureFlo, aptar4inject); broader portfolio but overlaps with Ypsomed in pharma elastomeric/combination products.
• Phillips-Medisize (Molex): Phillips-Medisize designs and manufactures drug-delivery devices including autoinjectors, inhalers, and connected platforms for pharma OEMs; competes with Ypsomed in design/development and assembly of self-injection systems.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ypsomed
• Facebookfacebook.com/ypsomed
• LinkedInlinkedin.com/company/22071

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ypsomed